Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
or

Kronos Bio Inc (KRON)

Kronos Bio Inc (KRON)
0.8800 +0.0100 (+1.15%) 16:00 ET [NASDAQ]
0.8800 x 215 0.9000 x 174
Realtime by (Cboe BZX)
0.8800 x 215 0.9000 x 174
Realtime - - (-) -
Quote Overview for Wed, Apr 16th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.8500
Day High
0.9000
Open 0.8600
Previous Close 0.8700 0.8700
Volume 73,274 73,274
Avg Vol 136,211 136,211
Stochastic %K 76.70% 76.70%
Weighted Alpha -23.84 -23.84
5-Day Change +0.1043 (+13.42%) +0.1043 (+13.42%)
52-Week Range 0.6900 - 1.6000 0.6900 - 1.6000
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 52,921
  • Shares Outstanding, K 60,969
  • Annual Sales, $ 9,850 K
  • Annual Income, $ -86,080 K
  • EBIT $ -93 M
  • EBITDA $ -94 M
  • 60-Month Beta 1.78
  • Price/Sales 5.31
  • Price/Cash Flow N/A
  • Price/Book 0.59
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.43
  • Most Recent Earnings $-0.43 on 03/18/25
  • Next Earnings Date 05/08/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 570.67% ( -20.70%)
  • Historical Volatility 43.71%
  • IV Percentile 88%
  • IV Rank 39.46%
  • IV High 1,311.46% on 04/17/24
  • IV Low 87.74% on 06/12/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 20
  • Volume Avg (30-Day) 32
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 986
  • Open Int (30-Day) 861

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.30
  • Number of Estimates 1
  • High Estimate -0.30
  • Low Estimate -0.30
  • Prior Year -0.50
  • Growth Rate Est. (year over year) +40.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7400 +19.11%
on 04/09/25
Period Open: 0.9400
0.9747 -9.57%
on 03/18/25
-0.0586 (-6.23%)
since 03/14/25
3-Month
0.7400 +19.11%
on 04/09/25
Period Open: 1.0100
1.0900 -19.14%
on 01/23/25
-0.1286 (-12.73%)
since 01/16/25
52-Week
0.6900 +27.74%
on 05/24/24
Period Open: 1.0900
1.6000 -44.91%
on 07/16/24
-0.2086 (-19.14%)
since 04/16/24

Most Recent Stories

More News
Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results

KRON : 0.8800 (+1.38%)
Kronos Bio Announces Leadership Change with Deborah Knobelman Appointed as President and Interim CEO

Kronos Bio appoints Deborah Knobelman as President and Interim CEO, succeeding Norbert Bischofberger amidst significant workforce reduction.Quiver AI SummaryKronos Bio, Inc. announced that Dr. Deborah...

KRON : 0.8800 (+1.38%)
Kronos Bio Stock Jumps After Deep Workforce Cuts And CEO Shuffle: Retail Aligns With Shake-Up

The company said this move is part of a broader strategy to implement cost-cutting measures.

IWC : 103.14 (-0.68%)
KRON : 0.8800 (+1.38%)
VXF : 160.66 (-1.10%)
VTI : 258.21 (-2.08%)
Kronos Bio Announces CEO Transition and Reduction in Force

KRON : 0.8800 (+1.38%)
Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024

KRON : 0.8800 (+1.38%)
Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives

KRON : 0.8800 (+1.38%)
Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma

KRON : 0.8800 (+1.38%)
Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors

KRON : 0.8800 (+1.38%)
Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors

KRON : 0.8800 (+1.38%)
Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease

KRON : 0.8800 (+1.38%)

Business Summary

Kronos Bio Inc. is a clinical-stage biopharmaceutical company. It engages in discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription. Kronos Bio Inc. is headquartered in San Mateo, Calif.

See More

Key Turning Points

3rd Resistance Point 0.9787
2nd Resistance Point 0.9493
1st Resistance Point 0.9087
Last Price 0.8800
1st Support Level 0.8387
2nd Support Level 0.8093
3rd Support Level 0.7687

See More

52-Week High 1.6000
Fibonacci 61.8% 1.2524
Fibonacci 50% 1.1450
Fibonacci 38.2% 1.0376
Last Price 0.8800
52-Week Low 0.6900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro